88 Ces Urol 2024; 28(2): 69–88 PŘEHLEDOVÉ ČLÁNKY 50. Muneer A, Kayes O, Ahmed HU, et al. Molecular prognostic factors in penile cancer. World J Urol. 2009; 27: 161–167. 51. Lopes A, Bezerra AL, Pinto CA, et al. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002; 168: 81–86. 52. Zargar-Shoshtari K, Spiess PE, Berglund AE, et al. Clinical Significance of p53 and p16(ink4a) status in a contemporary North American penile carcinoma cohort. Clin Genitourin Cancer. 2016; 14: 346–351. 53. Mohanty SK, Mishra SK, Bhardwaj N, et al. p53 and p16ink4a as predictive and prognostic biomar‑ kers for nodal metastasis and survival in a contemporary cohort of penile squamous cell carcinoma. Clin Genitourin Cancer. 2021; 19: 510–520. 54. Bowie J, Singh S, O’Hanlon C, et al. A systematic review of non-HPV prognostic biomarkers used in penile squamous cell carcinoma. Turk J Urol. 2021; 47(5): 358–365. 55. Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021; 27(17): 4685–4689. 56. Chahoud J, Gleber-Netto FO, McCormick BZ, et al. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021; 27(9): 2560–2570. 57. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008; 179(1): 53–56. 58. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immu‑ noglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887–3895. 59. Upadhaya S, Neftelinov ST, Hodge J, Campbell J. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 2022; 21(7): 482–483. 60. Davidsson S, Carlsson J, Giunchi F, et al. PD-L1 Expression in Men with Penile Cancer and its Associ‑ ation with Clinical Outcomes. Eur Urol Oncol. 2019; 2(2): 214–221. 61. Udager AM, Liu TY, Skala SL, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016; 27(9): 1706–1712. 62. Cocks M, Taheri D, Ball MW, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol. 2017; 59: 55–61. 63. De Bacco MW, Carvalhal GF, MacGregor B, et al. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region. Clin Genitourin Cancer. 2020; 18 (3): e254–e259.
RkJQdWJsaXNoZXIy NDA4Mjc=